Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany

BMC Health Services Research

Volumn 13, Issue 1, 2013, Pages

  Ultsch, Bernhard ^a,b   Weidemann, Felix ^a   Reinhold, Thomas ^b   Siedler, Anette ^a   Krause, Gérard ^a,c   Wichmann, Ole ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

Cost effectiveness; Herpes zoster; Markov; Postherpetic neuralgia; QALY; Vaccine

Indexed keywords

VARICELLA ZOSTER VACCINE;

AGED; ARTICLE; COST BENEFIT ANALYSIS; ECONOMIC MODEL; ECONOMICS; FEMALE; GERMANY; HEALTH CARE COST; HERPES ZOSTER; HUMAN; MALE; MARKOV CHAIN; MIDDLE AGED; NEURALGIA, POSTHERPETIC; POSTHERPETIC NEURALGIA; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; FEMALE; GERMANY; HEALTH CARE COSTS; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; NEURALGIA, POSTHERPETIC; QUALITY-ADJUSTED LIFE YEARS;

MLCS; MLOWN;

EID: 84884542243     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-13-359     Document Type: Article

References (86)

1. Vom Zwang zur Pockenschutzimpfung zum Nationalen Impfplan. Klein S, Schöneberg I, Krause G, Bundesgesundheitsbl 2012 55 11-12 1512 1523
2. Seroprevalence of varicella-zoster virus in the German population. Wutzler P, Färber I, Wagenpfeil S, Bisanz H, Tischer A, Vaccine 2001 20 1-2 121 124 (Pubitemid 32905323)
3. Varicella zoster virus: natural history and current therapies of varicella and herpes zoster. Breuer J, Whitley R, Herpes 2007 14 Suppl 2 25 29
4. The nature of Herpes Zoster: a long-term study and a new hypothesis. Hope-Simpson RE, Proc R Soc Med 1965 58 9 20
5. Varicella and herpes zoster. Part 1: virology, epidemiology, clinical picture, laboratory diagnostics. Wittek M, Doerr HW, Allwinn R, Med Klin (Munich) 2010 105 5 334 338
6. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. Schmader K, Gnann JW Jr, Watson CP, J Infect Dis 2008 197 Suppl 2 207 S215
7. A prospective study of the herpes zoster severity of illness. Drolet M, Brisson M, Levin MJ, Schmader KE, Oxman MN, Johnson RW, Camden S, Mansi JA, Clin J Pain 2010 26 8 656 666
8. Treatment of herpes zoster. Opstelten W, Eekhof J, Neven AK, Verheij T, Can Fam Physician 2008 54 3 373 377 (Pubitemid 351413661)
9. The Epidemiology and Prevention of Herpes Zoster. Forbes H, Thomas S, Langan S, Curr Dermat Rep 2012 1 1 39 47
10. Postherpetic neuralgia. Hope-Simpson RE, J R Coll Gen Pract 1975 25 157 571 575
11. Postherpetic neuralgia: a review. Jericho BG, Internet Journal of Pain, Symptom Control and Palliative Care 2010 8 1
12. Pain and its persistence in herpes zoster. Dworkin RH, Portenoy RK, Pain 1996 67 2-3 241 251 (Pubitemid 26375339)
13. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD, J Pain 2005 6 6 356 363 (Pubitemid 40804340)
14. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, Patrick D, Blanchette C, Mansi JA, CMAJ 2010 182 16 1731 1736
15. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, Chan IS, Choo P, Levin MJ, Johnson G, et al. Clin J Pain 2007 23 6 490 496 (Pubitemid 46956185)
16. Acute pain in herpes zoster and its impact on health-related quality of life. Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH, Clin Infect Dis 2004 39 3 342 348 (Pubitemid 39050481)
17. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Edmunds WJ, Brisson M, Rose JD, Vaccine 2001 19 23-24 3076 3090 (Pubitemid 32324035)
18. Epidemiology, outcome and control of varicella-zoster infection. Miller E, Marshall R, Vurdien J, Rev Med Microbiol 1993 4 4 222 230 (Pubitemid 23321790)
19. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, Roos L, De Serres G, Epidemiol Infect 2001 127 2 305 314 (Pubitemid 33019542)
20. The incidence of herpes zoster. Donahue JG, Choo PW, Manson JE, Platt R, Arch Intern Med 1995 155 15 1605 1609
21. Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. Ultsch B, Köster I, Reinhold T, Siedler A, Krause G, Icks A, Schubert I, Wichmann O, Eur J Health Econ 2012 1 12
22. Herpes zoster in Germany: quantifying the burden of disease. Ultsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O, BMC Infect Dis 2011 11 1 173
23. Herpes zoster in Deutschland-Eine retrospektive Analyse von GKV-Daten. Schiffner-Rohe J, Jow S, Lilie HM, Köster I, Schubert I, MMW Fortschr Med Originalien 2009 151 193 197
24. Current management of herpes zoster: the European view. Volpi A, Gross G, Hercogova J, Johnson RW, Am J Clin Dermatol 2005 6 5 317 325 (Pubitemid 41577406)
25. Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient. Johnson RW, Wasner G, Saddier P, Baron R, Drugs Aging 2008 25 12 991 1006
26. Does treatment of acute herpes zoster prevent or shorten postherpetic neuralgia? Alper BS, Lewis PR, J Fam Pract 2000 49 3 255 264 (Pubitemid 30461293)
27. Varicella and herpes zoster. Part 2: therapy and prevention. Wittek M, Doerr HW, Allwinn R, Med Klin (Munich) 2010 105 6 399 403
28. Herpes zoster guideline of the German Dermatology Society (DDG). Gross G, Schofer H, Wassilew S, Friese K, Timm A, Guthoff R, Pau HW, Malin JP, Wutzler P, Doerr HW, J Clin Virol 2003 26 3 277 289 discussion 291-273 (Pubitemid 36294104)
29. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, et al. N Engl J Med 2005 352 22 2271 2284
30. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Schmader KE, Levin MJ, Gnann JW, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su S-C, Clin Infect Dis 2012 54 7 922 928
31. Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged >= 50 Years [ClinicalTrials.gov Identifier NCT01165177] last update February 7, 2013 2013 http://clinicaltrials.gov/ct2/show/NCT01165177? term=herpes+zoster&spons=GlaxosmithKline&age=12&phase=2&rank=1
32. Do we fully understand the economic value of vaccines? Drummond M, Chevat C, Lothgren M, Vaccine 2007 25 32 5945 5957 (Pubitemid 47082460)
33. Gesetzliche Krankenversicherung Mitglieder,mitversicherte Angehörige und Krankenstand Monatswerte Januar-Mai 2013 2013 http:// bundesgesundheitsministerium.de/fileadmin/dateien/Downloads/Statistiken/GKV/ Mitglieder-Versicherte/KM1-Januar-Mai-2013.pdf
34. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. Annemans L, Bresse X, Gobbo C, Papageorgiou M, J Med Econ 2010 13 3 537 551
35. Estimating the number needed to vaccinate to prevent herpes zoster-related disease, health care resource use and mortality. Brisson M, Can J Public Health 2008 99 5 383 386
36. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Gauthier A, Breuer J, Carrington D, Martin M, Remy V, Epidemiol Infect 2009 137 1 38 47
37. Herpes zoster: burden of disease in France. Gonzalez Chiappe S, Sarazin M, Turbelin C, Lasserre A, Pelat C, Bonmarin I, Chosidow O, Blanchon T, Hanslik T, Vaccine 2010 28 50 7933 7938
38. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Max M, Schafer S, Culnane M, Smoller B, Dubner R, Gracely R, Neurology 1988 38 9 1427
39. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Opstelten W, Mauritz JW, de Wit NJ, van Wijck AJ, Stalman WA, van Essen GA, Fam Pract 2002 19 5 471 475 (Pubitemid 35244231)
40. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ, Vaccine 2009 27 9 1454 1467
41. Post-shingles neuralgia by any definition is painful, but is it PHN? Yawn BP, Mayo Clin Proc 2011 86 12 1141 1142
42. General Methods for Assessment of the Relation of Benefits to Costs https://www.iqwig.de/download/General-Methods-for-the-Assessment-of-the- Relation-of-Benefits-to-Costs.pdf
43. Cost estimation-working paper, Version 1.0 https://www.iqwig.de/download/ Working-Paper-Cost-Estimation.pdf
44. Clinical practice. Herpes zoster. Gnann JW Jr, Whitley RJ, N Engl J Med 2002 347 5 340 346
45. Population-based study of herpes zoster and its sequelae. Ragozzino MW, Melton LJ 3rd, Kurland LT, Chu CP, Perry HO, Medicine (Baltimore) 1982 61 5 310 316 (Pubitemid 12031812)
46. Herpes zoster Vaccine and the incidence of Recurrent Herpes Zoster in an immunocompetent elderly population. Tseng HF, Chi M, Smith N, Marcy SM, Sy LS, Jacobsen SJ, J Infect Dis 2012 55 10 1320 1328
47. Herpes zoster recurrences more frequent than previously reported. Yawn BP, Wollan PC, Kurland MJ, St Sauver JL, Saddier P, Mayo Clin Proc 2011 86 2 88 93
48. Bevölkerung und Erwerbstätigkeit-Sterbetafel Deutschland https://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Bevoelkerung/ Sterbefaelle/Tabellen/SterbetafelDeutschland.xls?-blob=publicationFile
49. Vaccines for preventing herpes zoster in older adults. Gagliardi AM, Gomes Silva BN, Torloni MR, Soares BG, Cochrane Database Syst Rev 2012 10 D008858
50. Vaccination against Herpes Zoster and Postherpetic Neuralgia. Oxman MN, Levin MJ, J Infect Dis 2008 197 Suppl 2 228 S236
51. FDA Clinical Briefing Document for Merck & Co., Inc. Zoster vaccine live (Oka/Merck) Zostavax™ FDA, Vaccines and Related Biological Products Advisory Committee, US-Food-and-Drug-Administration, 2005
52. Persistence of Zoster Vaccine Efficacy. Schmader K, Oxman M, Levin M, Betts R, Morrison V, Gelb L, Johnson G, Zhang J, Li X, Annunziato P, ICAAC/IDSA: 2008; Durham 2008
53. Persistence of the Efficacy of Zoster Vaccine in the Shingles prevention study and the short-term persistence substudy. Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, Morrison VA, Gelb L, Guatelli JC, Harbecke R, et al. Clin Infect Dis 2012
54. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium. Bilcke J, Marais C, Ogunjimi B, Willem L, Hens N, Beutels P, Vaccine 2012 30 3 675 684
55. Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice? Bilcke J, Ogunjimi B, Hulstaert F, Van Damme P, Hens N, Beutels P, Vaccine 2012 30 17 2795 2800
56. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Pellissier JM, Brisson M, Levin MJ, Vaccine 2007 25 49 8326 8337 (Pubitemid 350087379)
57. MMWR, Noninfluenza Vaccination Coverage Among Adults-United States 2011 http://www.cdc.gov/mmwr/pdf/wk/mm62e0129.pdf
58. Epidemiologisches Bulletin https://www.rki.de/DE/Content/Infekt/EpidBull/ Archiv/2002/Ausgabenlinks/16-02.pdf?-blob=publicationFile
59. Lauer-Taxe online-Preisinfo: ZOSTAVAX 2010 http://www2.lauer-fischer.de/ home/
60. Briggs A, Claxton K, Sculpher M, Decision modelling for health economic evaluation Oxford: Oxford University Press 2008
61. [The quality of life questionnaire EQ-5D: modelling and norm values for the general population]. Hinz A, Klaiberg A, Brahler E, Konig HH, Psychother Psychosom Med Psychol 2006 56 2 42 48 (Pubitemid 44525090)
62. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M, Brazier J, O'Hagan T, Health Econ 2005 14 4 339 347 (Pubitemid 40514748)
63. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Welte R, Feenstra T, Jager H, Leidl R, Pharmacoeconomics 2004 22 13 857 876 (Pubitemid 39273956)
64. Pharmaceutical Policies in OECD Countries. Jacobzone S, Reconciling Social and Industrial Goals Paris: OECD, 40 OLMaSPOPN, 2000
65. Postherpetic neuralgia in Europe: The scale of the problem and outlook for the future. Mick G, Hans G, J Clin Gerontol Geriatr 2013
66. Natural History of Herpes Zoster: Late follow-up 3.9 yrs (n= 43) and 7.7 yrs (n= 10). Reda H, Greene K, Rice FL, Rowbotham MC, Petersen KL, PAIN 2013 10 2227 2233
67. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. van Lier A, van Hoek AJ, Opstelten W, Boot H, de Melker H, BMC Health Serv Res 2010 10 1 237
68. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. De Boer PT, Pouwels KB, Cox JM, Hak E, Wilschut JC, Postma MJ, Vaccine 2013 31 9 1276 1283
69. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Szucs TD, Kressig RW, Papageorgiou M, Kempf W, Michel JP, Fendl A, Bresse X, Hum Vaccin 2011 7 7 749 756
70. Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis. Bresse X, Annemans L, Preaud E, Bloch K, Duru G, Gauthier A, Expert Rev Pharmacoecon Outcomes Res 2013 13 3 393 406
71. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Moore L, Remy V, Martin M, Beillat M, McGuire A, Cost Effectiveness and Resource Allocation 2010 8 1 7
72. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Hornberger J, Robertus K, Ann Intern Med 2006 145 5 317 325 (Pubitemid 46768588)
73. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Rothberg MB, Virapongse A, Smith KJ, Clin Infect Dis 2007 44 10 1280 1288 (Pubitemid 46717289)
74. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Brisson M, Pellissier JM, Camden S, Quach C, De Wals P, Hum Vaccin 2008 4 3 238 245
75. Cost effectiveness of herpes zoster vaccine in Canada. Najafzadeh M, Marra CA, Galanis E, Patrick DM, Pharmacoeconomics 2009 27 12 991 1004
76. A systematic review of the cost effectiveness of herpes zoster vaccination. Szucs TD, Pfeil AM, Pharmacoeconomics 2013 31 2 125 136
77. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, Johnson G, Bauer M, Williams HM, Kaplan KM, et al. J Pain 2004 5 6 344 356 (Pubitemid 39164674)
78. Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years. Bala MV, Wood LL, Zarkin GA, Norton EC, Gafni A, O'Brien B, Journal of clinical epidemiology 1998 51 8 667 676 (Pubitemid 28404361)
79. Die deutsche Version des EuroQol-Fragebogens. Graf Von Der Schulenburg JM, Claes C, Greiner W, et al. Zeitschrift für Gesundheitswissenschaften 1998 6 3 20 (Pubitemid 28113724)
80. Subjective Social Status and Health-Related Quality of Life among Adults in Germany. Hoebel J, Kuntz B, Muters S, Lampert T, Gesundheitswesen 2013
81. Health status of the German population: results of a representative survey using the EuroQol questionnaire. Konig HH, Bernert S, Angermeyer MC, Gesundheitswesen 2005 67 3 173 182 (Pubitemid 40523398)
82. Health status of adults in Germany: results from a representative survey using the EuroQol 5D (EQ-5D). Mielck A, Vogelmann M, Schweikert B, Leidl R, Gesundheitswesen 2010 72 8-9 476 486
83. Epidemiological characteristics and societal burden of varicella zoster virus in the Netherlands. Pierik J, Gumbs P, Fortanier S, Van Steenwijk P, Postma M, BMC Infect Dis 2012 12 1 110
84. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. Gialloreti L, Merito M, Pezzotti P, Naldi L, Gatti A, Beillat M, Serradell L, di Marzo R, Volpi A, BMC Infect Dis 2010 10 1 230
85. Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian community of Spain. Cebrian-Cuenca A, Diez-Domingo J, San-Martin-Rodriguez M, Puig-Barbera J, Navarro-Perez J, BMC Infect Dis 2011 11 1 302
86. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax§ssup§®§esup§) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules. Vesikari T, Hardt R, Rümke HC, Icardi G, Montero J, Thomas S, Sadorge C, Fiquet A, Human Vaccines & Immunotherapeutics 2013 9 4 854 860